SIGLEC6 is a sialic acid-binding immunoglobulin-like lectin that functions as an adhesion molecule recognizing alpha-2,6-linked sialic acids on cell surfaces 1. The protein is expressed on specific immune cell subsets, including AXL+SIGLEC6+ dendritic cells (ASDCs) that circulate for approximately 2.16 days and are rapidly recruited to inflammatory sites 23. In leukemia, SIGLEC6 is highly expressed on acute myeloid leukemia (AML) blasts and leukemic stem cells but absent from normal hematopoietic stem and progenitor cells, making it an attractive therapeutic target 4. SIGLEC6 CAR T-cell therapy effectively eliminates AML cells by suppressing the SHP2/Src/ERK/IL-3 signaling axis 5. Beyond malignancy, SIGLEC6 engages inhibitory pathways relevant to mast cell silencing in chr19 urticaria treatment 67. In reproduction, embryonic SIGLEC6 interacts with sialylated CD44 in the endometrium to facilitate embryo implantation 1. Clinically, circulating SIGLEC6 levels are markedly elevated (9.5-fold) in preeclampsia and correlate with disease severity, emerging as a potential biomarker 8.